Albireo Pharma, Inc., a Delaware corporation (the “Issuer”).
Item 1(b). | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES |
53 State Street, 19th Floor
Boston, MA 02109
Item 2(a). | NAME OF PERSON FILING |
This statement is filed by:
(i) Double Black Diamond Offshore Ltd., a Cayman Islands exempted company (the “Double Offshore”), with respect to Common Stock, par value $0.01 per share, of the Issuer (the “Common Stock”) held or beneficially owned directly by it;
(ii) Black Diamond Arbitrage Offshore Ltd., a Cayman Islands exempted company (“Arbitrage Offshore”), with respect to the Common Stock held or beneficially owned directly by it;
(iii) EDCA 2019 Fund, L.P., a Delaware limited partnership (“EDCA”), with respect to the Common Stock held or beneficially owned directly by it;
(iv) Corbin Hedged Equity Fund, L.P., a Delaware Limited Partnership (“Corbin,” and together with Double Offshore, Arbitrage Offshore and EDCA, the “Funds”), with respect to the Common Stock directly held by it;
(v) Carlson Capital, L.P., a Delaware limited partnership (“Carlson Capital”), which serves as the investment manager to the Funds with respect to any shares of Common Stock held by the Funds;
(vi) Asgard Investment Corp. II, a Delaware corporation (“Asgard II”), which serves as the general partner of Carlson Capital, with respect to the Common Stock directly held by the Funds; and
(vii) Mr. Clint D. Carlson, a United States citizen (“Mr. Carlson”), who is the sole stockholder of Asgard II and serves as president of Asgard II and Carlson Capital, with respect to the Common Stock directly held by the Funds.
The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons”.
The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.
Item 2(b). | ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE |
The address of the principal business office of each of the Reporting Persons is 2100 McKinney Avenue, Suite 1900, Dallas, Texas 75201.
9